Enzalutamide or MDV-3100 (IUPAC name: 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide) is a potent AR signaling inhibitor approved to treat patients with metastatic castration-resistant prostate cancer [12]. Here, AR is linked to prostate carcinoma.